Arlington Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Arlington Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-28,810	Closed	-$2.8M	–	98
2023 Q1	$2.8M	Buy	28,810 +17,693	+159%	+$1.83M	2.63%	11
2022 Q4	$1.15M	Buy	+11,117	New	+$1.04M	1.29%	24
2015 Q3	–	Sell	-50,369	Closed	-$6.98M	–	19
2015 Q2	$6.98M	Buy	50,369 +5,380	+12%	+$667K	4.67%	9
2015 Q1	$5.61M	Buy	44,989 +18,550	+70%	+$1.97M	4.02%	9
2014 Q4	$2.39M	Buy	+26,439	New	+$2.2M	2.02%	15

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Arlington Capital Management's BMRN Position: Q2 2023 in Review

Arlington Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 28,810 shares — an estimated $2.8M sold.

Arlington Capital Management first reported a position in BMRN in Q4 2014 and held it in 5 quarters. The position peaked at $6.98M in Q2 2015. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Arlington Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Arlington Capital Management sold 28,810 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $2.8M.
Arlington Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Arlington Capital Management's BioMarin Pharmaceuticals position peaked at $6.98M in Q2 2015.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Arlington Capital Management's 13F filing for Q2 2023, filed 24 Aug 2023.